- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05837052
A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC
A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Treatment for Patients With Stage IIIB-IVA Oligometastatic Non-small Cell Lung Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This single-arm, open-label, prospective phase II clinical trial was designed to evaluate the efficacy and safety of Serplulimab plus chemotherapy as conversion treatment in patients with stage IIIB-IVA oligometastatic non-small cell lung cancer.
The primary endpoints were the rate of NSCLC converting to resectable tumors and the 1-year progression-free survival (PFS) rate.The secondary endpoints included the rates of R0 resection, major pathological response (MPR) and pathological complete response (pCR), overall survival (OS) and PFS. Multi-omics analysis will be performed to identify potential biomarkers for treatment response.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Peng Zhao, MD
- Phone Number: +86-18767186629
- Email: zhaop@zju.edu.cn
Study Contact Backup
- Name: Jian Hu, MD
- Phone Number: +86-18767186629
- Email: dr_hujian@zju.edu.cn
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310058
- Recruiting
- Zhejiang University
-
Contact:
- Lulu Liu
- Email: weijiafang@zju.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients should voluntarily join this study and sign the informed consent form
- NSCLC patients diagnosed by cytology or histology and not previously receiving anti-tumor treatments (including systemic treatments, local treatments .etc)
- Patients with IIIB - IVA oligometastatic NSCLC : (a) IIIB - IIIC stage (T1-4N2-3): patients are not suitable or refuse to receive upfront surgical resection or radiotherapy; (b) oligometastatic stage IV (T1-3N0-2): radical resection/radiotherapy is feasible for metastatic lesions (the number of metastases being up to 3, and the maximum diameter of metastases being up to 2cm)
- After evaluation by MDT, upfront surgical resection is not the preferred treatment, but after induction systemic treatments, radical resection of the primary tumor is feasible, and radical resection/radiotherapy is feasible for extrathoracic metastases (if any)
- Age from 18 to 75 years old, both male and female
- ECOG score 0-1
- According to the RECIST v1.1 , patients should have at least one measurable lesion
- For suspicious mediastinal lymph nodes (including pathological enlargement or PET-CT indicating malignancy, etc.), further sampling is required for pathological diagnosis by EUBS, thoracoscopy, or mediastinoscopy
- According clinical evaluation, the lung function of patients (such as FVC, FEV1, TLC, FRC, DLco, etc.) should be sufficient for pneumonectomy
- The function of important organs should meet the following requirements: absolute count of neutrophils ≥ 1.5 × 109/L; Platelets ≥ 100 × 109/L; Hemoglobin ≥ 90g/L; Serum albumin ≥ 35g/L; Thyroid hormone (TSH) ≤ 1 × ULN; Serum bilirubin ≤ 1.5 × ULN; ALT and AST ≤ 3 × ULN; International standardized ratio (INR) ≤ 1.5 or prothrombin time (PT) ≤ 1.5 × ULN; Serum creatinine ≤ 1.5 × ULN
- Female patients at childbearing age are required to use contraceptive measures; for male patients whose partners are women at childbearing age, effective methods of contraception should be used during the trial period
Exclusion Criteria:
Patients who meet any of the following conditions will not be enrolled in this study:
- NSCLC patients have sensitive EGFR mutation, EML4-ALK fusion or other forms of ALK gene changes
- Patients have previously received immune checkpoint inhibitors such as PD-1/ PD-L1/CTLA4 antibody
- Patients with other primary malignancies within the past 3 years (excluding cured skin basal cell carcinoma and cervical carcinoma in situ)
- Patients with active hepatitis B/C
- Patients with any active autoimmune diseases or a history of autoimmune diseases
- Patients who are using immunosuppressive agents or require systemic hormone therapy
- Patients with hypertension but without good control even through antihypertensive medication treatment ; patients with clinical symptoms or diseases related to unsatisfying cardiac function
- Patients with abnormal coagulation function (INR>2.0, PT>16s)
- Arterial/venous thrombotic events occurred before screening within 6 months
- Patients with active infection
- Patients with congenital or acquired immune dysfunction (such as HIV infection)
- According to the judgment of the researchers, patients have other factors that may affect the results of the research or cause the research to be terminated
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Serplulimab plus chemotherapy
Patients with unresectable NSCLC will receive 3-4 cycles of serplulimab plus chemotherapy as the conversion treatment (serplulimab 300mg d1 q3w; carboplatin (AUC 5) on day 1, and pemetrexed (500 mg/m2 for adenocar- cinoma) or nab-paclitaxel (260 mg/m2 for squamous carcinoma) d1 q3w), and then curative pneumonectomy will be provided for patients who are suitable for primary tumor resection.
Locoregional ablative treatments will be performed for metastatic lesions.
Maintenance treatment with PD-1 antibody q3w will continue up to 12 months or disease progression after surgery.
|
Patients with unresectable NSCLC will receive serplulimab plus chemotherapy as conversion treatment, and then curative pneumonectomy will be provided for patients who are suitable for primary tumor resection.
Locoregional ablative treatments will be performed for metastatic lesions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the rate of NSCLC converting to resectable tumors
Time Frame: up to 16 weeks
|
the proportion of unresectable NSCLC patients who are converted to being suitable for radical pneumonectomy after 3-4 cycles serplulimab plus chemotherapy
|
up to 16 weeks
|
the 1-year progression-free survival (PFS) rate
Time Frame: up to one year
|
the proportion of patients who are progression-free after pneumonectomy
|
up to one year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the rate of R0 resection
Time Frame: immediately after the surgery
|
the proportion of R0 resection in patients who receive pneumonectomy
|
immediately after the surgery
|
Progression-free survival (PFS)
Time Frame: up to five years
|
The duration from the date of initial treatment to the date of disease progression or death due to any cause
|
up to five years
|
Overall survival (OS)
Time Frame: up to five years
|
The duration from the date of initial treatment to the date of death due to any cause
|
up to five years
|
the rate of major pathological response (MPR)
Time Frame: up to 16 weeks
|
the proportion of patients who achieve MRP among those receiving pneumonectomy
|
up to 16 weeks
|
the rate of pathological complete response (pCR)
Time Frame: up to 16 weeks
|
the proportion of patients who achieve pCR among those receiving pneumonectomy
|
up to 16 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Weijia Fang, MD, The First Affiliated Hospital, Zhejiang University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CTHLX10
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Unresectable Lung Non-Small Cell Carcinoma
-
National Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Unresectable Lung Non-Small Cell Carcinoma | Unresectable Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic...United States
-
Ohio State University Comprehensive Cancer CenterNational Institute on Aging (NIA)RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell Carcinoma | Unresectable Lung Non-Small Cell Carcinoma | Advanced Lung Non-Small Cell Carcinoma | Advanced... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterNational Institute on Aging (NIA)CompletedStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Advanced Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell Carcinoma | Unresectable Lung Non-Small Cell Carcinoma | Unresectable Lung CarcinomaUnited States
-
Shanghai Chest HospitalUnknownUnresectable Stage III Non-small-cell Lung CancerChina
-
MedImmune LLCCompletedStage III Non-small Cell Lung Cancer | UnresectableUnited States, Canada, Italy, Spain, France, Hong Kong, Portugal, Taiwan, Poland
-
National Cancer Institute (NCI)AstraZenecaActive, not recruitingMetastatic Lung Non-Small Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Advanced Malignant Solid Neoplasm | Unresectable Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IIIA Lung Non-Small... and other conditionsUnited States, Canada
-
TheraOpAstraZenecaActive, not recruitingStage III Non-small Cell Lung Cancer | Locally Advanced | UnresectableSwitzerland
-
Nanfang Hospital of Southern Medical UniversityChia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownUnresectable Stage III Non-small Cell Lung CancerChina
-
National Cancer Institute (NCI)NRG OncologyRecruitingStage III Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Unresectable Lung Non-Small Cell Carcinoma | Locally Advanced Lung Non-Small Cell Carcinoma | Locally Recurrent Lung Non-Small Cell CarcinomaUnited States
-
University of PennsylvaniaTerminatedNon-small Cell Lung Cancer | Starting Pemetrexed Based Therapy | Unresectable CancerUnited States
Clinical Trials on serplulimab plus chemotherapy as conversion treatment
-
The First Hospital of Jilin UniversityNot yet recruiting
-
South London and Maudsley NHS Foundation TrustCompletedAttention Deficit Hyperactivity DisorderUnited Kingdom
-
Centre for Addiction and Mental HealthCompleted
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH)Completed
-
University of IndianapolisUniversity of Missouri, Kansas City; Missouri State UniversityCompletedHypertension | Diabete Type 2United States
-
Nova Scotia Health AuthorityCompletedEating DisordersCanada
-
Chang Gung Memorial HospitalMinistry of Science and Technology, TaiwanCompleted
-
Vapotherm, Inc.Knox Community Hospital; Riverside Regional Medical Center; Midwest Chest ConsultantsCompleted
-
Second Affiliated Hospital of Guangzhou Medical...RecruitingMelanoma | Cervical Cancer | Breast Cancer | Head and Neck Cancer | Ovarian Cancer | Lung Cancer | Pancreas Cancer | Colo-rectal Cancer | Renal Cancer | HepatocarcinomaChina
-
Yale UniversityNational Institute on Drug Abuse (NIDA)Completed